Appointments enhance governance and strategic oversight as Space-Eyes prepares to operate as a publicly traded company following proposed business combination with McKinley Acquisition Corp.
Hemodynamic Monitoring Devices Market Set to Hit USD 2.57 Billion by 2035 at 5.90% CAGR, Driven by Critical Care and AI Adoption | SNS Insider
The U.S. Hemodynamic Monitoring Devices Market to reach USD 0.89 Billion and Europe USD 0.71 Billion by 2035, supported by expanding ICU capacity, rising surgical volumes, and growing adoption of AI-enabled, predictive and non-invasive monitoring technologies.
The U.S. Hemodynamic Monitoring Devices Market to reach USD 0.89 Billion and Europe USD 0.71 Billion by 2035, supported by expanding ICU capacity, rising surgical volumes, and growing adoption of AI-enabled, predictive and non-invasive monitoring technologies.
Hemodynamic Monitoring Devices Market Set to Hit USD 2.57 Billion by 2035 at 5.90% CAGR, Driven by Critical Care and AI Adoption | SNS Insider
The U.S. Hemodynamic Monitoring Devices Market to reach USD 0.89 Billion and Europe USD 0.71 Billion by 2035, supported by expanding ICU capacity, rising surgical volumes, and growing adoption of AI-enabled, predictive and non-invasive monitoring technologies.
The U.S. Hemodynamic Monitoring Devices Market to reach USD 0.89 Billion and Europe USD 0.71 Billion by 2035, supported by expanding ICU capacity, rising surgical volumes, and growing adoption of AI-enabled, predictive and non-invasive monitoring technologies.
Chesapeake Fine Food Group, LLC Acquires Harrington’s of Vermont, Expanding Its Family of Heritage American Brands
Owings Mills, MD, Aug. 21, 2026 (GLOBE NEWSWIRE) — Chesapeake Fine Food Group, LLC, parent company of Mackenzie Limited and Chesapeake Bay Crab Cakes and More, announced today the acquisition of Harrington’s of Vermont, the premium purveyor of gourmet smoked hams and meats whose recipes and smokehouse traditions have graced American tables for over 153 years.
MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product, Continuing Its Strategic Investment in Bitcoin-Related Assets
MicroCloud Hologram Inc. Announces Acquisition of 140,268 MSTR Shares Through Structured Note Investment Product
Quantum X Labs Announces Additional Advancement in Quantum Error Correction Using NVIDIA CUDA-Q with New Results on Google’s Dataset
QXL’s updated AI-driven decoder demonstrated improved performance supporting the Company’s roadmap toward reliable fault-tolerant quantum computing
Vivakor Reports Positive Operating Income as Second Quarter Revenue Increases 10% to $32.1 Million
Dallas, TX, Aug. 21, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse and remediation services, today announced financial results for the three and six months ended June 30, 2026, highlighted by second-quarter revenue growth, a 45% increase in second-quarter gross profit and a return to positive operating income.
reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform
Acquisition adds multi-state direct lending with in-house underwriting and funding, expanding reAlpha’s integrated mortgage platform across 38 states and Washington, D.C.
Acquisition adds multi-state direct lending with in-house underwriting and funding, expanding reAlpha’s integrated mortgage platform across 38 states and Washington, D.C.
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., today announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics’ neridronate development program in Complex Regional Pain Syndrome Type 1 (“CRPS-1”, formerly known as Reflex Sympathetic Dystrophy). Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.
Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers
Company explores additional growth opportunities, including the possible acquisition of AI-Based Technologies, Cybersecurity or Data Centers, while continuing its existing business activities
Linear Alkyl Benzene Market Size to Surpass USD 17.86 Billion by 2035; Growing at 4.60% CAGR | SNS Insider
U.S. Market to Hit USD 2.86 Billion and Europe USD 2.52 Billion by 2035 as Detergent Demand and Biodegradable Surfactant Use Support Growth
U.S. Market to Hit USD 2.86 Billion and Europe USD 2.52 Billion by 2035 as Detergent Demand and Biodegradable Surfactant Use Support Growth
Gulf & Pacific Equities Corp. reports on 2026 Semi-Annual Results with Revenue of $2,356,856
Toronto, Aug. 21, 2026 (GLOBE NEWSWIRE) — Gulf & Pacific Equities Corp. (TSX-V: GUF), an established company focused on the acquisition, management and development of anchored shopping centers in Western Canada, reports a 4.4% increase in revenue to $2,356,856 for the six months ended June 30, 2026, from $2,257,363 for the same period last year.
Bunker Hill and Silver47 Announce Merger to Create a ‘Made in America’ U.S. Silver & Critical Minerals Champion
KELLOGG, Idaho and VANCOUVER, British Columbia, Aug. 21, 2026 (GLOBE NEWSWIRE) — Bunker Hill Mining Corp. (“Bunker Hill”) (TSX: BNKR | OTCQB: BHLL), and Silver47 Exploration Corp. (“Silver47”) (TSXV: AGA | OTCQX: AAGAF | Frankfurt: QP2) are pleased to announce that they have entered into a definitive arrangement agreement dated August 20, 2026 (the “Arrangement Agreement”) pursuant to which Bunker Hill has agreed to acquire all of the issued and outstanding common shares of Silver47 by way of a plan of arrangement (the “Transaction”). Concurrent with the Transaction, the combined company (the “Combined Company”) will seek a name change to “Bunker Hill Silver Corp.” and remain listed on the Toronto Stock Exchange (“TSX”).
Brantone Veylor Launches Its European Strategic Expansion
Brantone Veylor Launches Its European Strategic Expansion
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson today announced that the European Commission (EC) has approved an indication extension for TECVAYLI® (teclistamab) in combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces a new treatment option as early as second line for patients living with RRMM.
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson today announced that the European Commission (EC) has approved an indication extension for TECVAYLI® (teclistamab) in combination with daratumumab for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. The approval introduces a new treatment option as early as second line for patients living with RRMM.
STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week
STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week
Knowledge Returns Alliance Expands AI-Enabled Financial Education Through PF System
COLORADO SPRINGS, Colo., Aug. 21, 2026 (GLOBE NEWSWIRE) — Knowledge Returns Alliance (KRA) is expanding the integration of financial education, applied research, and artificial intelligence through the continued development of its Precision Focus System (PF System). The initiative reflects KRA’s broader effort to equip learners with the financial knowledge, analytical capabilities, and technology awareness increasingly required across modern financial markets.